Forbion hires Novo Ventures' Lüneborg

Lüneborg joins from Novo Ventures, where she worked on late-stage biopharmaceutical investments. She has prior experience with Apposite Capital, as well as at Cancer Research, where she worked as a business analyst.

In her role at Forbion, Lüneborg will relocate from Denmark to the Netherlands. She will be responsible for Forbion's debut growth fund. Forbion Growth Opportunities Fund I held a EUR 185m first close in July 2020, followed by a final close in April 2021 on EUR 360m, surpassing its EUR 250m target.

Forbion's Growth Opportunities Fund I backs syndicated rounds of EUR 100m-200m, providing growth capital for mature clinical-development companies, pre-IPO funding, and capital injections in companies that are already listed on European stock exchanges. The fund expects to make 10-12 platform investments and deploys equity tickets of EUR 15m-35m.

Forbion's flagship strategy generally targets earlier-stage opportunities, including companies created by Forbion. The latest fund in the strategy, Forbion V, held a final close in December 2020 on its EUR 460m hard-cap, as reported.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• People
• Benelux
• GPs
• Healthcare
• Netherlands